Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Goodrich Katherine reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals director Katherine Goodrich received new equity awards as part of her non-employee director compensation. She was granted 2,417 restricted stock units, each representing one share of common stock, and stock options for 3,837 shares with a strike price of $64.34. Both the RSUs and options vest in full one year after the June 25, 2026 grant date, contingent on her continued board service.
Tarsus Pharmaceuticals director Andrew D. Goldberg received new equity awards as part of his compensation for serving as a non-employee director. He was granted 2,417 Restricted Stock Units, each representing a contingent right to receive one share of Tarsus common stock. He also received a stock option covering 3,837 shares of common stock at an exercise price of $64.34 per share. Both the RSUs and the option were granted in connection with the company’s 2026 annual meeting of stockholders and will vest in full on the one-year anniversary of the grant date, subject to his continuous board service.
Tarsus Pharmaceuticals director Morrison Scott W received new equity awards tied to his service as a non-employee director. He was granted 2,417 Restricted Stock Units, each representing a right to receive one share of common stock, and 3,837 stock options to buy common stock at an exercise price of $64.34 per share.
Both the RSUs and options were granted as of the company’s 2026 annual meeting of stockholders and will vest in full on the one-year anniversary of the grant date, subject to his continuous service. Following these grants, his reported holdings in these specific RSU and option awards are 2,417 and 3,837 units, respectively.
Tarsus Pharmaceuticals, Inc. reported that director Bhaskar Chaudhuri received new equity awards as part of his compensation for serving as a non-employee director at the company’s 2026 annual meeting of stockholders. He was granted 2,417 Restricted Stock Units, each representing one share of common stock, and a stock option for 3,837 shares of common stock at an exercise price of $64.34 per share. Both the RSUs and the option vest in full on the one-year anniversary of the June 25, 2026 grant date, subject to his continuous service on the board.
Tarsus Pharmaceuticals director Wendy L. Yarno received new equity awards as part of her non-employee director compensation for the company’s 2026 annual meeting. She was granted 1,209 and 2,417 restricted stock units, each RSU equal to one common share, plus an option for 3,837 shares at an exercise price of $64.34. The option vests in full one year after grant, while the RSUs vest either fully after one year or in four scheduled installments, all subject to continued board service. These are compensation grants, not open-market share purchases or sales.
Tarsus Pharmaceuticals director David E.I. Pyott received new equity awards tied to his service as a non-employee director at the company’s 2026 annual meeting of stockholders. The grants are compensation awards, not open-market purchases or sales.
He was granted 806 restricted stock units (RSUs) and an additional 2,417 RSUs, each representing one share of common stock. One RSU grant vests in full on the one-year anniversary of the June 25, 2026 grant date, while the other vests in four equal installments on September 15, 2026, December 15, 2026, March 15, 2027, and June 15, 2027, in each case subject to his continuous service.
Pyott also received a stock option for 3,837 shares of common stock at an exercise price of $64.34 per share, expiring on June 24, 2036. This annual option grant will vest in full on the one-year anniversary of the grant date, contingent on his continued service as a non-employee director.
Tarsus Pharmaceuticals director William J. Link, PhD reported equity awards tied to his service as a non-employee director as of the company’s 2026 annual meeting of stockholders. He received grants of restricted stock units and stock options that provide future rights to Tarsus common shares.
The filing shows 3,837 stock options with an exercise price of $64.34 per share, vesting in full on the one-year anniversary of the grant date and expiring on June 24, 2036, subject to continued service. It also reports RSU awards covering 806 and 2,417 shares, with one grant vesting in full after one year and the other vesting in four equal installments from September 15, 2026 through June 15, 2027.
Tarsus Pharmaceuticals, Inc. held its annual stockholder meeting on June 25, 2026. A total of 38,237,214 shares were represented in person or by proxy, out of 43,023,959 shares of common stock outstanding and entitled to vote as of the record date, establishing a quorum.
Stockholders elected four Class III directors — Wendy Yarno, Andrew Goldberg, Scott Morrison, and David E.I. Pyott — to serve until the 2029 annual meeting, with each nominee receiving substantially more votes for than withheld. Several other directors will continue serving under existing terms.
Stockholders also approved, on an advisory and non‑binding basis, the compensation of the company’s named executive officers, with 34,486,767 votes for and 238,014 against. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 38,219,521 votes for and minimal opposition.
Tarsus Pharmaceuticals President and CEO Bobak R. Azamian, through the Bobak Azamian Living Trust, sold a total of 10,000 shares of common stock in open-market transactions on June 17, 2026 under a pre-arranged Rule 10b5-1 trading plan. The trust continues to hold 847,991 shares indirectly, and Azamian also holds 33,421 shares directly, indicating these sales represent a small portion of his overall stake.
Tarsus Pharmaceuticals officer Jeffrey S. Farrow reported RSU vesting and a related tax transaction. On June 15, 2026, 27,881 Restricted Stock Units settled into the same number of common shares at a conversion price of $0.00 per share. On June 16, 2026, 14,396 of these shares were sold at $60.95 per share to cover tax withholding obligations under a mandatory “sell to cover” election by the company, so the sale was not a discretionary trade. After these transactions, Farrow directly owns 56,801 shares of Tarsus common stock. The RSUs were granted on April 24, 2023 and vest 25% each June 15 from 2024 through 2027, subject to his continuous service.